Rheumatoid arthritis treatment has been revolutionized by biologic disease-modifying anti-rheumatic drugs (DMARDs) and JAK inhibitors. Methotrexate, anti-TNF agents, anti-IL-6 (tocilizumab, sarilumab), B-cell depletion (rituximab), T-cell costimulation modulation (abatacept), and JAK inhibitors (tofacitinib, baricitinib, upadacitinib) all have established roles. Despite multiple options, treatment-resistant RA remains common and research continues. For patients with RA, clinical trials for rheumatoid arthritis can offer access to investigational therapies. This guide covers how to find RA trials, active research areas, and resources.
Categories of RA trials
Active RA trials in 2026 include:
Next-generation biologics: More selective inhibitors of IL-6, IL-17, and other cytokines; novel mechanisms targeting inflammatory pathways.
JAK inhibitor refinements: More selective JAK inhibitors with improved safety profiles given the cardiovascular and malignancy concerns with current JAK inhibitors.
Bispecific antibodies: Targeting multiple cytokines simultaneously.
Cell therapies: CAR-T approaches in autoimmune disease showing promising early data; specific RA trials.
Repair-promoting agents: Therapies aimed at promoting cartilage repair beyond just controlling inflammation.
Treatment-resistant RA: Trials specifically for patients who’ve failed multiple biologics.
Where to find RA trials
Resources:
- ClinicalTrials.gov
- Arthritis Foundation
- American College of Rheumatology
- Major academic rheumatology programs
Typical eligibility for RA trials
Common inclusion criteria:
- Confirmed RA diagnosis meeting ACR/EULAR criteria
- Active disease (specific DAS28, swollen/tender joint counts)
- Inadequate response to methotrexate or biologics (varies by trial)
- Stable medications for specified period
Common exclusion criteria:
- Other inflammatory joint conditions
- Active infection
- Active malignancy
- Pregnancy
- Significant cardiovascular disease for some trials
Frequently Asked Questions
Are trials for biologic-naive RA available?
Yes. Trials enroll across treatment lines.
What’s special about CAR-T for autoimmune disease?
Anti-CD19 CAR-T cells have shown remarkable efficacy in some autoimmune diseases, including SLE and RA. Active research with growing trial activity.
Are JAK inhibitor trials still active given safety concerns?
Yes, with focus on more selective inhibitors that may have better safety profiles.
How long do RA trials typically last?
Phase 3 trials are typically 24-52 weeks with longer-term extensions.
Can I be in an RA trial if I have other autoimmune diseases?
Depends on the trial. Some exclude other autoimmune conditions; others permit certain comorbidities.
The bottom line on RA trials
RA research includes novel mechanisms, more selective JAK inhibitors, and emerging cell therapies. Arthritis Foundation and academic rheumatology centers provide trial resources. Discuss with your rheumatologist as part of treatment planning.